Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Combination Therapies in Metastatic Castration-Resistant Prostate Cancer
NCT03431350Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Mar 2018; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03431350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431350.